187 related articles for article (PubMed ID: 30368687)
1. Medical therapy for non-functioning pituitary tumors-a critical approach.
Tampourlou M; Karapanou O; Vassiliadi DA; Tsagarakis S
Hormones (Athens); 2019 Jun; 18(2):117-126. PubMed ID: 30368687
[TBL] [Abstract][Full Text] [Related]
2. Clinically non-functioning pituitary adenomas: Pathogenic, diagnostic and therapeutic aspects.
Mercado M; Melgar V; Salame L; Cuenca D
Endocrinol Diabetes Nutr; 2017; 64(7):384-395. PubMed ID: 28745610
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological Treatment of Non-Functioning Pituitary Adenomas.
Vargas-Ortega G; Gonzalez-Virla B; Romero-Gameros CA
Arch Med Res; 2023 Dec; 54(8):102917. PubMed ID: 37996269
[TBL] [Abstract][Full Text] [Related]
4. Advances in the medical and surgical treatment of pituitary adenomas: the role of long-acting somatostatin analogs. Participants of the "Conference on Medical and Surgical Treatment of Pituitary Adenomas" (Zürich, 5th October, 1991).
Fahlbusch R; Giovanelli M; Buchfelder M; Losa M
J Endocrinol Invest; 1993 Jun; 16(6):449-60. PubMed ID: 8370920
[No Abstract] [Full Text] [Related]
5. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours.
Colao A; Filippella M; Pivonello R; Di Somma C; Faggiano A; Lombardi G
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S57-S63. PubMed ID: 17413190
[TBL] [Abstract][Full Text] [Related]
6. Pituitary tumor transforming gene and insulin-like growth factor 1 receptor expression and immunohistochemical measurement of Ki-67 as potential prognostic markers of pituitary tumors aggressiveness.
Sánchez-Tejada L; Sánchez-Ortiga R; Moreno-Pérez O; Montañana CF; Niveiro M; Tritos NA; Alfonso AM
Endocrinol Nutr; 2013; 60(7):358-67. PubMed ID: 23416216
[TBL] [Abstract][Full Text] [Related]
7. Long-term control of a MEN1 prolactin secreting pituitary carcinoma after temozolomide treatment.
Philippon M; Morange I; Barrie M; Barlier A; Taieb D; Dufour H; Conte-Devolx B; Brue T; Castinetti F
Ann Endocrinol (Paris); 2012 Jun; 73(3):225-9. PubMed ID: 22520146
[TBL] [Abstract][Full Text] [Related]
8. Management of NFAs: medical treatment.
Even-Zohar N; Greenman Y
Pituitary; 2018 Apr; 21(2):168-175. PubMed ID: 29344905
[TBL] [Abstract][Full Text] [Related]
9. The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro.
Gruszka A; Kunert-Radek J; Radek A; Pisarek H; Taylor J; Dong JZ; Culler MD; Pawlikowski M
Life Sci; 2006 Jan; 78(7):689-93. PubMed ID: 16115652
[TBL] [Abstract][Full Text] [Related]
10. [Treatment of pituitary adenomas].
Mezosi E; Nemes O
Orv Hetil; 2009 Sep; 150(39):1803-10. PubMed ID: 19758960
[TBL] [Abstract][Full Text] [Related]
11. Control of pituitary adenoma cell proliferation by somatostatin analogs, dopamine agonists and novel chimeric compounds.
Zatelli MC; Ambrosio MR; Bondanelli M; Uberti ECD
Eur J Endocrinol; 2007 Apr; 156 Suppl 1():S29-S35. PubMed ID: 17413185
[TBL] [Abstract][Full Text] [Related]
12. Dopamine agonist therapy of clinically non-functioning pituitary macroadenomas. Is there a role for 123I-epidepride dopamine D2 receptor imaging?
de Herder WW; Reijs AE; Feelders RA; van Aken MO; Krenning EP; Tanghe HL; van der Lely AJ; Kwekkeboom DJ
Eur J Endocrinol; 2006 Nov; 155(5):717-23. PubMed ID: 17062888
[TBL] [Abstract][Full Text] [Related]
13. Cabergoline should be attempted in progressing non-functioning pituitary macroadenoma.
Greenman Y; Bronstein MD
Eur J Endocrinol; 2021 Aug; 185(4):D11-D20. PubMed ID: 34288884
[TBL] [Abstract][Full Text] [Related]
14. Medical therapies in pituitary adenomas: Current rationale for the use and future perspectives.
Cuny T; Barlier A; Feelders R; Weryha G; Hofland LJ; Ferone D; Gatto F
Ann Endocrinol (Paris); 2015 Feb; 76(1):43-58. PubMed ID: 25556152
[TBL] [Abstract][Full Text] [Related]
15. TBR-760, a Dopamine-Somatostatin Compound, Arrests Growth of Aggressive Nonfunctioning Pituitary Adenomas in Mice.
Halem HA; Hochgeschwender U; Rih JK; Nelson R; Johnson GA; Thiagalingam A; Culler MD
Endocrinology; 2020 Aug; 161(8):. PubMed ID: 32591776
[TBL] [Abstract][Full Text] [Related]
16. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and treatment of pituitary adenomas.
Chanson P; Salenave S
Minerva Endocrinol; 2004 Dec; 29(4):241-75. PubMed ID: 15765032
[TBL] [Abstract][Full Text] [Related]
18. Endoscopic endonasal surgery for giant pituitary adenomas: advantages and limitations.
Koutourousiou M; Gardner PA; Fernandez-Miranda JC; Paluzzi A; Wang EW; Snyderman CH
J Neurosurg; 2013 Mar; 118(3):621-31. PubMed ID: 23289816
[TBL] [Abstract][Full Text] [Related]
19. Medical approach to pituitary tumors.
Neggers SJ; van der Lely AJ
Handb Clin Neurol; 2014; 124():303-16. PubMed ID: 25248595
[TBL] [Abstract][Full Text] [Related]
20. [Medical treatment of pituitary adenoma].
Chanson P
Rev Prat; 1996 Jun; 46(12):1509-13. PubMed ID: 8881166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
